 Shares of CASI Pharmaceuticals NASDAQ:CASI moved higher by 1.6 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 43.75 year over year to 0.09, which missed the estimate of 0.08.Revenue of 2,671,000 higher by 0.00 year over year, which missed the estimate of 3,750,000.Outlook CASI Pharmaceuticals hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 10, 2020View more earnings on CASITime: 04:30 PMET Webcast URL: Companys 52-week high was at 3.82Companys 52-week low was at 1.15Price action over last quarter: Up 10.34Company Overview CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.See more from Benzinga Recap: Chimerix Q2 Earnings Recap: Momenta Pharmaceuticals Q2 Earnings Recap: Amicus Therapeutics Q2 EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 